Emergent BioSolutions | EBS - 现金及等价物



金融业
股票价格
USD
资产
USD 1.82B
现金及等价物
USD 111.7M
销售成本
USD 381.2M
流动资产
USD 679.5M
流动负债
USD 651.3M
债务
USD 903.2M
股息收益率
0
EBIT
USD -148.1M
EBITDA
USD -113.5M
员工
1.6K
EPS每股收益
USD -0.77
股本和储备
USD 649.3M
销售毛利
USD 10M
债务利息支出
USD 17.9M
贷款资金
USD 446.5M
市值
USD 437.5M
净收入
USD -261.3M
营业费用
USD 555.9M
营业利润
USD -218M
普通股股本
USD 100K
PE价格收益
14.4
税前利润
USD -130.8M
销售收入
USD 276.6M
销售和管理费用
USD 182.8M
股票
USD 328.9M
贸易债权人
USD 112.2M
应收帐款人
USD 290.1M


现金及等价物 更改 日
Acadia Pharmaceuticals USD 819.69M 27.33M 2025-12
Akebia Therapeutics USD 184.84M 18.4M 2025-12
ALKERMES USD 388.57M 227.88M 2025-12
Alnylam Pharmaceuticals USD 1.66B 167M 2025-12
Amarin USD 122.8M 25.08M 2025-09
ANI Pharmaceuticals USD 285.58M 22.98M 2025-12
BioMarin Pharmaceutical USD 1.31B 61.57M 2025-12
Coherus Biosciences USD 88.88M 14.47M 2025-12
Emergent BioSolutions USD 111.7M 23.9M 2023-12
Exelixis USD 482.49M 106.19M 2025-12
Glaxosmithkline GBP 3.3B 303M 2025-09
Heron Therapeutics USD 43.07M 26.55M 2025-09
Ionis Pharmaceuticals USD 2.68B 437M 2025-12
Ironwood Pharmaceuticals USD 140.41M 47.56M 2025-09
Lexicon Pharmaceuticals USD 21.36M 41.52M 2025-06
Lonza CHF 719M 188M 2025-12
Merck USD 18.17B 10.16B 2025-09
Moderna USD 2.6B 1.46B 2025-12
Myriad Genetics USD 149.6M 4.2M 2025-12
Nektar Therapeutics USD 15.12M 25.92M 2025-12
Neurocrine Biosciences USD 713M 372.8M 2025-12
Pacira USD 158.54M 10.96M 2025-12
Pfizer USD 1.34B 295M 2025-09
PTC Therapeutics USD 984.65M 312.03M 2025-12
Sanofi EUR 7.66B 1.25B 2025-12
Sarepta Therapeutics USD 801.28M 188.2M 2025-12
United Therapeutics USD 1.56B 217M 2025-12
Vanda Pharmaceuticals USD 84.85M 14.83M 2025-12
Xoma USD 143.9M 7.68M 2024-06